A Night for the Next Breakthrough: Our 2026 Gala
Dr. Albert Bourla, Dr. Robbie Majzner and Einat Dado Baralia came together in New York for our third annual gala, a conversation about getting promising science to children in time.
On October 19, the Chairman and CEO of Pfizer sat on a stage in New York beside a pediatric cancer researcher and a mother who lost her son to neuroblastoma.
Dr. Albert Bourla, Dr. Robbie Majzner and our founder, Einat Dado Baralia, came together for A Night for the Next Breakthrough, our third annual gala at Port Sa’id. Moderated by Tamar Ish Shalom, their conversation centered on getting promising science to children in time.
Scenes from A Night for the Next Breakthrough, October 19, 2026.
The voices that brought us together
Board member Alan S. Roemer welcomed guests with an invitation to give “not only in your wallet, but in your heart.” In a video address early in the evening, Israel’s President Isaac Herzog recognized Einat’s determination:
“She has continued to insist: where a solution does not yet exist, it is our job to find one.”
Einat recalled the family, nurses, doctors and researchers who carried them through Shir’s treatment, and a little boy who laughed as he rode his bike through hospital hallways, his family following with the IV pole.
She spoke of lorlatinib, a Pfizer drug she believes gave their family precious extra months together. “Albert, that is a Pfizer drug. Thank you.” It is now being studied in a phase 3 trial for newly diagnosed high-risk neuroblastoma with ALK alterations.
“Time is life”
The panel brought together Shir for Life’s “Golden Triangle”: industry, science and parent advocacy. Bourla described their distinct roles: researchers bring innovation, families bring “the sense of urgency,” and industry brings investment and the capacity to develop medicines through years of uncertainty.
“We need all three of them,” he said.
He addressed the difficulty of attracting investment in rare diseases and called for sustained incentives that reflect the long timelines of drug development. A phrase he recalled from Pfizer’s vaccine-development effort captured the stakes: “Time is life.”
Majzner, of Dana-Farber Cancer Institute and Harvard Medical School and a member of our Scientific Board, explained neuroblastoma’s complexity: “No two cases are ever the same.” His lab works on CAR T-cell therapies, which engineer immune cells to recognize cancer.
He described how academic teams can develop treatments for early testing, building evidence for industry to take them further. Philanthropy can support ideas that do not yet have the data traditional grants often require.
“New drugs come out of ideas that are different than what we’ve done,” Majzner said.
For Einat, the urgency was painfully familiar. When her family sought another trial for Shir, doctors could not be certain he would live long enough to take part. Her appeal was to open possibilities earlier, while children are still strong enough to receive them.
What your support has built
Since last year’s gala, your support has helped carry forward the work that began with Shir.
Our webinars and knowledge library now connect a community across nearly 60 countries. This year, we signed our fourth research project overall, our second in Israel, and committed to funding a Clinical Research Coordinator for a new study in Israel.
Shir for Life’s impact film, shown at the gala.
Guests also heard the Aronson family’s story and met their son, Maayan Chaim, through a film that brought the discussion back to the families behind the research.
Maayan’s story.
The panel was followed by a live auction and special appeal supporting pre-clinical research.
Thank you
Thank you to Dr. Bourla and Pfizer, our event sponsor; Dr. Majzner and Tamar; President Herzog; the Aronson family; and Gila Filosof for her artwork.
We are grateful to our Board of Directors, Talia Cohen, Alan S. Roemer, Yael Ron and Sharon Zicherman, and to our Advocacy Partners, Recordati and SERB Pharmaceuticals.
To every guest, donor, partner and friend: thank you for helping sustain this work.
Einat’s closing appeal looked toward the next child who will need help:
“Let’s make sure we get to him on time.”
Recent posts
A Night for the Next Breakthrough: Our 2026 Gala
Shir for Life and ICRF partner to fund neuroblastoma tumor microbiome research
From One Family’s Loss to a Global Movement for Children With Neuroblastoma